334 related articles for article (PubMed ID: 34254868)
1. Recent advances in herbal combination nanomedicine for cancer: delivery technology and therapeutic outcomes.
Anwar DM; El-Sayed M; Reda A; Fang JY; Khattab SN; Elzoghby AO
Expert Opin Drug Deliv; 2021 Nov; 18(11):1609-1625. PubMed ID: 34254868
[No Abstract] [Full Text] [Related]
2. Opportunities and challenges for co-delivery nanomedicines based on combination of phytochemicals with chemotherapeutic drugs in cancer treatment.
Gao Q; Feng J; Liu W; Wen C; Wu Y; Liao Q; Zou L; Sui X; Xie T; Zhang J; Hu Y
Adv Drug Deliv Rev; 2022 Sep; 188():114445. PubMed ID: 35820601
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
4. Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs.
Huang W; Chen L; Kang L; Jin M; Sun P; Xin X; Gao Z; Bae YH
Adv Drug Deliv Rev; 2017 Jun; 115():82-97. PubMed ID: 28624478
[TBL] [Abstract][Full Text] [Related]
5. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
6. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
7. Nanocarriers overcoming biological barriers induced by multidrug resistance of chemotherapeutics in 2D and 3D cancer models.
Petrikaite V; D'Avanzo N; Celia C; Fresta M
Drug Resist Updat; 2023 May; 68():100956. PubMed ID: 36958083
[TBL] [Abstract][Full Text] [Related]
8. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
9. Combination antitumor therapy with targeted dual-nanomedicines.
Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q
Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
11. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer.
Castillo RR; Colilla M; Vallet-Regí M
Expert Opin Drug Deliv; 2017 Feb; 14(2):229-243. PubMed ID: 27402029
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib repurposing in cancer therapy: molecular mechanisms and nanomedicine-based delivery technologies.
Khafaga AF; Shamma RN; Abdeen A; Barakat AM; Noreldin AE; Elzoghby AO; Sallam MA
Nanomedicine (Lond); 2021 Aug; 16(19):1691-1712. PubMed ID: 34264123
[TBL] [Abstract][Full Text] [Related]
13. "Combo" nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy.
Kemp JA; Shim MS; Heo CY; Kwon YJ
Adv Drug Deliv Rev; 2016 Mar; 98():3-18. PubMed ID: 26546465
[TBL] [Abstract][Full Text] [Related]
14. Boosting Nanomedicine Efficacy with Hyperbaric Oxygen Therapy.
Wang X; Li S; Liu X; Wu X; Ye N; Yang X; Li Z
Adv Exp Med Biol; 2021; 1295():77-95. PubMed ID: 33543456
[TBL] [Abstract][Full Text] [Related]
15. Advances in oral delivery of anti-cancer prodrugs.
Jain AK; Jain S
Expert Opin Drug Deliv; 2016 Dec; 13(12):1759-1775. PubMed ID: 27292717
[TBL] [Abstract][Full Text] [Related]
16. Gold Complexes in Anticancer Therapy: From New Design Principles to Particle-Based Delivery Systems.
Moreno-Alcántar G; Picchetti P; Casini A
Angew Chem Int Ed Engl; 2023 May; 62(22):e202218000. PubMed ID: 36847211
[TBL] [Abstract][Full Text] [Related]
17. Overcoming multidrug resistance with nanomedicines.
Ganoth A; Merimi KC; Peer D
Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
[TBL] [Abstract][Full Text] [Related]
18. Combinations of chemo-, immuno-, and gene therapies using nanocarriers as a multifunctional drug platform.
Hopkins C; Javius-Jones K; Wang Y; Hong H; Hu Q; Hong S
Expert Opin Drug Deliv; 2022 Oct; 19(10):1337-1349. PubMed ID: 35949105
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy.
Hafez DA; Hassanin IA; Teleb M; Khattab SN; Elkhodairy KA; Elzoghby AO
Nanomedicine (Lond); 2021 Oct; 16(25):2305-2325. PubMed ID: 34551585
[TBL] [Abstract][Full Text] [Related]
20. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
